Evidence map›Paper›PMID 38685603›Full record

ArticleESC heart failure2024

Prognostic impact of heart failure admission in survivors of acute myocardial infarction.

Satoshi Takeuchi, Satoshi Honda, Kensaku Nishihira, Sunao Kojima, Misa Takegami, Yasuhide Asaumi, Mike Saji, Jun Yamashita, Kiyoshi Hibi, Jun Takahashi and 7 more

Abstract readMulticenter Study
In one paragraph

Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Astragaloside IV inhibits MAPK pathway and promotes mitochondrial autophagy in rats with heart failure.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Satoshi TakeuchiDepartment of Cardiovascular Medicine, Tohoku University, Sendai, Japan.ORCID https://orcid.org/0000-0001-6649-358X
Satoshi HondaDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre, Suita, Japan.
Kensaku NishihiraDepartment of Cardiovascular Medicine, Miyazaki Medical Association Hospital, Miyazaki, Japan.
Sunao KojimaDepartment of Internal Medicine, Sakurajyuji Yatsushiro Rehabilitation Hospital, Yatsushiro, Japan.
Misa TakegamiDepartment of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Centre, Suita, Japan.
Yasuhide AsaumiDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre, Suita, Japan.
Mike SajiDepartment of Cardiology, Sakakibara Heart Institute, Fuchu, Japan.
Jun YamashitaDepartment of Cardiology, Tokyo Medical University Hospital, Tokyo, Japan.
Kiyoshi HibiDepartment of Cardiovascular Medicine, Yokohama City University Medical Centre, Yokohama, Japan.
Jun TakahashiDepartment of Cardiovascular Medicine, Tohoku University, Sendai, Japan.
Yasuhiko SakataDepartment of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre, Suita, Japan.
Morimasa TakayamaDepartment of Cardiology, Sakakibara Heart Institute, Fuchu, Japan.
Tetsuya SumiyoshiDepartment of Cardiology, Sakakibara Heart Institute, Fuchu, Japan.
Hisao OgawaKumamoto University, Kumamoto, Japan.
Kazuo KimuraDepartment of Cardiovascular Medicine, Yokohama City University Medical Centre, Yokohama, Japan.
Satoshi YasudaDepartment of Cardiovascular Medicine, Tohoku University, Sendai, Japan.
JAMIR Investigators

Funding

Daiichi-Sankyo
6 · The paper itself

Abstract

aimsThe incidence and prognosis of symptomatic heart failure following acute myocardial infarction (AMI) in the primary percutaneous coronary intervention era have rarely been reported in the literature. This study aimed to (i) determine the incidence of heart failure admission among AMI survivors, (ii) compare 1 year outcomes between patients with heart failure admission and those without, and (iii) identify the independent risk factors associated with heart failure admission. METHODS AND

resultsThe Japan Acute Myocardial Infarction Registry is a prospective multicentre registry from which data on consecutively enrolled patients with AMI from 50 institutions between 2015 and 2017 were obtained. Among the 3411 patients enrolled, 3226 who survived until discharge were included in this study. The primary endpoint was all-cause mortality. The secondary endpoints were major adverse cardiovascular events (defined as cardiovascular mortality, non-fatal myocardial infarction, or non-fatal cerebral infarction) and major bleeding events corresponding to Bleeding Academic Research Consortium Type 3 or 5. Clinical outcomes were compared between the patients who were and were not admitted for heart failure. Over a median follow-up of 12 months, 124 patients (3.8%) were admitted due to heart failure. Independent risk factors for heart failure admission included older age, female sex, Killip class ≥2 on admission, left ventricular ejection fraction <40%, estimated glomerular filtration rate ≤30 mL/min/1.73 m

conclusionsUtilizing real-world data of the contemporary percutaneous coronary intervention era from the Japan Acute Myocardial Infarction Registry database, this study demonstrates that the heart failure admission of AMI survivors was significantly associated with higher all-cause mortality rates.

Indexed as

Heart FailureMyocardial InfarctionRegistriesAgedCause of DeathFemaleFollow-Up StudiesHospitalizationHumansIncidenceJapanMaleMiddle AgedPercutaneous Coronary InterventionPrognosisProspective StudiesAcute myocardial infarctionHeart failurePercutaneous coronary interventionRegistry

Identifiers

PMID38685603
PMCPMC11287335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.